Skip to content

Olecranon Bursitis

Prefer to watch? 5-minute lesson13 slides · same content, shorter

1 · SNAPSHOT

Olecranon Bursitis body chart
Illustrative, not diagnostic. Canva body chart for Olecranon Bursitis.

Visually alarming, usually benign, and the two tempting treatments are the two that cause the trouble.

Illness script in one line: a localised, often dramatic swelling over the point of the elbow that hurts far less than it looks, following a knock, a fall, or weeks of leaning on a desk or a floor — with full but uncomfortable end-range flexion and an otherwise normal elbow.

Caseload frequency: common enough that you'll see it on placement. Read further: risk factors in a large-scale population-based study [1], trauma-related cases [2][3], superficial bursitis [4].

The bursa is superficial, and everything you put through the skin costs something

This is the organising idea, and it reverses the instinct. The olecranon bursa sits directly under thin, mobile, poorly vascularised skin with bone immediately behind it. Aspirating it and injecting it both feel like doing something. Both cross that skin.

And the boring option has actually been randomised. Read further: a randomised trial of compression plus non-steroidal anti-inflammatory drugs and other approaches [5], a commentary on it [6], non-surgical treatment of aseptic olecranon bursitis [7], treatment [8].

The reframe:

The instinctThe better position
"It's full of fluid — drain it"Compression has a randomised trial. Aspiration doesn't fix why it filled
"Inject it and it'll settle"Long-term follow-up of corticosteroid injection for traumatic olecranon bursitis exists [9]. Ask yourself why that study was needed
The swelling is the problemThe swelling is the symptom. The elbow that keeps meeting a surface is the problem

First-line management, for a reason: activity modification and protective padding.

Members

The 5-minute lesson is for members

Twelve slides on this pattern: what you'll hear, what to examine, what to do. Free with an account.

Sign in or join free

Guideline anchor

No Australian guideline, and no clinical practice guideline for the aseptic condition.

More

The management anchor is a systematic review of non-surgical treatment of aseptic olecranon bursitis (Kaur et al. 2023, PMID 37945181), with treatment systematically reviewed earlier (Sayegh et al. 2014, PMID 25234151) and clinical management reviewed in the Journal of Hand Surgery (Nchinda et al. 2021, PMID 33840568). The single most useful study is a randomised trial in Clinical Orthopaedics and Related Research comparing compression plus NSAIDs against other approaches (Kim et al. 2016, PMID 26463567), published with a CORR Insights commentary (Kennedy et al. 2016, PMID 26493988). For the condition this page exists to exclude, the 2023 French recommendations on prepatellar and olecranon septic bursitis apply (Darrieutort-Laffite et al. 2024, PMID 37995861).

PubMed Source

None of these is a clinical practice guideline for aseptic bursitis, because none exists. The French recommendations govern the septic condition — the thing this page exists to exclude — and are medical, not physiotherapy, documents.

Members

The evidence summary is for members

Verified diagnostic accuracy, where the evidence stands and what it doesn't settle. Free with an account.

Sign in or join free

Sources · 20

Show

Every source on this page resolves and title-verifies against PubMed. Newest first.

  1. 2024Shemesh et al. (2024). Risk Factors for the Development of Olecranon Bursitis-A Large-Scale Population-Based Study. Journal of clinical medicine, 13(24). https://doi.org/10.3390/jcm13247801
  2. 2022Subramanian et al. (2022). Olecranon Bursitis Secondary to Trauma. Cureus, 14(7), e27306. https://doi.org/10.7759/cureus.27306
  3. 2017Raas et al. (2017). Treatment and outcome with traumatic lesions of the olecranon and prepatellar bursa: a literature review apropos a retrospective analysis including 552 cases. Archives of orthopaedic and trauma surgery, 137(6), 823-827. https://doi.org/10.1007/s00402-017-2690-2
  4. 2017Khodaee (2017). Common Superficial Bursitis. American family physician, 95(4), 224-231. PubMed 28290630
  5. 2016Kim et al. (2016). A Randomized Trial Among Compression Plus Nonsteroidal Antiinflammatory Drugs, Aspiration, and Aspiration With Steroid Injection for Nonseptic Olecranon Bursitis. Clinical orthopaedics and related research, 474(3), 776-83. https://doi.org/10.1007/s11999-015-4579-0
  6. 2016Kennedy (2016). CORR Insights(®): A Randomized Trial Among Compression Plus Nonsteroidal Antiinflammatory Drugs, Aspiration, and Aspiration With Steroid Injection for Nonseptic Olecranon Bursitis. Clinical orthopaedics and related research, 474(3), 784-6. https://doi.org/10.1007/s11999-015-4608-z
  7. 2023Kaur et al. (2023). Non-surgical treatment of aseptic olecranon bursitis: A systematic review. Reumatologia clinica, 19(9), 482-487. https://doi.org/10.1016/j.reumae.2023.05.004
  8. 2014Sayegh & Strauch (2014). Treatment of olecranon bursitis: a systematic review. Archives of orthopaedic and trauma surgery, 134(11), 1517-36. https://doi.org/10.1007/s00402-014-2088-3
  9. 1984Weinstein et al. (1984). Long-term follow-up of corticosteroid injection for traumatic olecranon bursitis. Annals of the rheumatic diseases, 43(1), 44-6. https://doi.org/10.1136/ard.43.1.44
  10. 2023Nguyen et al. (2023). Characteristics and management of olecranon or prepatellar septic bursitis. Infectious diseases now, 53(2), 104652. https://doi.org/10.1016/j.idnow.2023.104652
  11. 2024Darrieutort-Laffite et al. (2024). 2023 French recommendations for diagnosing and managing prepatellar and olecranon septic bursitis. Joint bone spine, 91(2), 105664. https://doi.org/10.1016/j.jbspin.2023.105664
  12. 2015Celli (2015). Triceps tendon rupture: the knowledge acquired from the anatomy to the surgical repair. Musculoskeletal surgery, 99 Suppl 1, S57-66. https://doi.org/10.1007/s12306-015-0359-y
  13. 2026Holt et al. (2026). Case Report: Chronic Olecranon Bursitis as a Risk Factor for Squamous Cell Carcinoma. Journal of orthopaedic case reports, 16(3), 149-153. https://doi.org/10.13107/jocr.2026.v16.i03.6922
  14. 2022Beyde et al. (2022). Efficacy of empiric antibiotic management of septic olecranon bursitis without bursal aspiration in emergency department patients. Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, 29(1), 6-14. https://doi.org/10.1111/acem.14406
  15. 2019Wu et al. (2019). Clinical efficacy of ultrasound-guided injection in the treatment of olecranon subcutaneous bursitis. Journal of X-ray science and technology, 27(6), 1145-1153. https://doi.org/10.3233/XST-190562
  16. 2024McDermott et al. (2024). Intrabursal Doxycycline Sclerotherapy for Recurrent Olecranon Bursitis of the Elbow: A Case Control Study. Journal of hand surgery global online, 6(4), 504-509. https://doi.org/10.1016/j.jhsg.2024.03.006
  17. 2024Simpson et al. (2024). No Wound Healing Complications or Recurrences Were Seen and a High Level of Satisfaction Was Reported in Patients Who Underwent Endoscopic Olecranon Bursectomy for Recalcitrant Olecranon Bursitis. Arthroscopy, sports medicine, and rehabilitation, 6(1), 100832. https://doi.org/10.1016/j.asmr.2023.100832
  18. 2024Shen et al. (2024). Clinical efficacy of endoscopic debridement combined with compression suture in the treatment of recalcitrant aseptic olecranon bursitis. Journal of orthopaedic surgery and research, 19(1), 596. https://doi.org/10.1186/s13018-024-05090-3
  19. 2013Tu et al. (2013). Olecranon extrabursal endoscopic bursectomy. Techniques in hand & upper extremity surgery, 17(3), 173-5. https://doi.org/10.1097/BTH.0b013e31829c0535
  20. 2021Nchinda & Wolf (2021). Clinical Management of Olecranon Bursitis: A Review. The Journal of hand surgery, 46(6), 501-506. https://doi.org/10.1016/j.jhsa.2021.02.006

Did this page do its job?

CliniStudy is in beta. One tap is enough — it decides what gets fixed first.